The experimental Novo Nordisk diabetes drug liraglutide has been found to be more efficient in helping people with diabetes to control blood sugar, when compared to older medicine .
58 per cent of diabetes patients who completed the trial using the Novo injectable medicine reached and maintained target blood glucose levels, compared to just 37 per cent who used glimepiride.
Dr. Alan Garber of the Baylor College of Medicine in Houston reportedly commented: “People overall lose weight with liraglutide. That’s a significant value-added benefit to this class of drugs . We were able to show that the safety risks of hypoglycemia are 10 times greater with the sulfonlyurea than with liraglutide because it has a completely different biochemical mechanism of action. To top it all off the blood sugar control with this agent is almost twice as good as with a maximum dose of what most people consider to be the best of the sulfonylureas.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…